Literature DB >> 7371472

A non-transferrin-bound serum iron in idiopathic hemochromatosis.

R G Batey, P Lai Chung Fong, S Shamir, S Sherlock.   

Abstract

The nature of iron in the serum of patients with idiopathic hemochromatosis has been studied utilizing an isotope labeling method and results have been compared with those from normal individuals and patients with other forms of liver disease. Between 2 and 4% of a tracer dose of 59Fe added to normal serum was retained by DEAE Sephadex and has been designated non-transferrin-bound. Alcoholic liver disease, chronic active hepatitis, and iron deficiency have no effect on this fraction. In idiopathic hemochromatosis 34.6 +/- 3.9% of the added iron was not bound to transferrin at diagnosis, representing approximately 700 microgram Fe/liter serum. Treatment lowers this fraction before serum iron concentration falls to normal. The majority of the non-transferrin-bound iron is of low molecular weight and is not bound to albumin. The presence of this fraction may contribute significantly to the development of tissue siderosis.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7371472     DOI: 10.1007/bf01308057

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  13 in total

1.  Distribution of storage iron as body stores expand in patients with hemochromatosis.

Authors:  L S Valberg; J B Simon; P N Manley; W E Corbett; J Ludwig
Journal:  J Lab Clin Med       Date:  1975-09

2.  FERROKINETICS: A STUDY OF TRANSPORT IRON IN PLASMA.

Authors:  F HOSAIN; C A FINCH
Journal:  J Lab Clin Med       Date:  1964-12

3.  The plasma-to-cell cycle of transferrin.

Authors:  J H JANDL; J H KATZ
Journal:  J Clin Invest       Date:  1963-03       Impact factor: 14.808

4.  State of iron(3) in normal human serum: low molecular weight and protein ligands besides transferrin.

Authors:  B Sarkar
Journal:  Can J Biochem       Date:  1970-12

5.  International committee for standardization in hematology. Proposed recommendations for measurement of serum iron in human blood.

Authors: 
Journal:  Br J Haematol       Date:  1971-04       Impact factor: 6.998

6.  Tissue iron distribution in idiopathic hemochromatosis.

Authors:  L S Valberg
Journal:  Gastroenterology       Date:  1978-11       Impact factor: 22.682

7.  Serum ferritin in patients with iron overload and with acute and chronic liver diseases.

Authors:  J Prieto; M Barry; S Sherlock
Journal:  Gastroenterology       Date:  1975-03       Impact factor: 22.682

8.  Idiopathic hemochromatosis in a young female. A case study and review of the syndrome in young people.

Authors:  J M Lamon; S P Marynick; R Roseblatt; S Donnelly
Journal:  Gastroenterology       Date:  1979-01       Impact factor: 22.682

9.  Hepatic iron deposition in humans. I. First-pass hepatic deposition of intestinally absorbed iron in patients with low plasma latent iron-binding capacity.

Authors:  R A Fawwaz; H S Winchell; M Pollycove; T Sargent
Journal:  Blood       Date:  1967-10       Impact factor: 22.113

10.  Hepatic iron clearance from serum in treated hemochromatosis.

Authors:  R G Batey; J E Pettit; A W Nicholas; S Sherlock; A V Hoffbrand
Journal:  Gastroenterology       Date:  1978-11       Impact factor: 22.682

View more
  27 in total

Review 1.  Immune cell functions in iron overload.

Authors:  M de Sousa
Journal:  Clin Exp Immunol       Date:  1989-01       Impact factor: 4.330

2.  Relationship between free iron and glycated hemoglobin in uncontrolled type 2 diabetes patients associated with complications.

Authors:  Jeevan K Shetty; Mungli Prakash; Mohammad S Ibrahim
Journal:  Indian J Clin Biochem       Date:  2008-03-06

3.  Transferrin receptor 2: continued expression in mouse liver in the face of iron overload and in hereditary hemochromatosis.

Authors:  R E Fleming; M C Migas; C C Holden; A Waheed; R S Britton; S Tomatsu; B R Bacon; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-29       Impact factor: 11.205

Review 4.  Pharmacology of iron transport.

Authors:  Shaina L Byrne; Divya Krishnamurthy; Marianne Wessling-Resnick
Journal:  Annu Rev Pharmacol Toxicol       Date:  2012-09-27       Impact factor: 13.820

5.  The effect of non-transferrin-bound iron on murine T lymphocyte subsets: analysis by clonal techniques.

Authors:  M F Good; L W Powell; J W Halliday
Journal:  Clin Exp Immunol       Date:  1987-10       Impact factor: 4.330

6.  Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload.

Authors:  B S van Asbeck; H A Verbrugh; B A van Oost; J J Marx; H W Imhof; J Verhoef
Journal:  Br Med J (Clin Res Ed)       Date:  1982-02-20

7.  Properties and hepatic metabolism of non-transferrin-bound iron.

Authors:  R G Batey; S Shamir; J Wilms
Journal:  Dig Dis Sci       Date:  1981-12       Impact factor: 3.199

8.  Efficient clearance of non-transferrin-bound iron by rat liver. Implications for hepatic iron loading in iron overload states.

Authors:  P Brissot; T L Wright; W L Ma; R A Weisiger
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

9.  Monocyte-macrophage ferric reductase activity is inhibited by iron and stimulated by cellular differentiation.

Authors:  J Partridge; D F Wallace; K B Raja; J S Dooley; A P Walker
Journal:  Biochem J       Date:  1998-12-15       Impact factor: 3.857

10.  Growth of human tumor cell lines in transferrin-free, low-iron medium.

Authors:  V Neumannova; D R Richardson; K Kriegerbeckova; J Kovar
Journal:  In Vitro Cell Dev Biol Anim       Date:  1995-09       Impact factor: 2.416

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.